CREDIT study is a series clinical trials performed by 40 clinical centers in China.

March 22, 2014  the FIM clinical trial 4M OCT and Angio result was first reported on CIT 2014 in Shanghai

International Sourcing Promotion Center.

OCT & Angio results suggest a high degree of safety and Efficacy of the second generation of Excel biodegradable polymer stent.

CREDIT I study indicates the second generation of EXCEL stents system has a good clinical performance.

Maintain effectiveness, lower Late Lumen Loss (LLL) on the basis of endothelial change quickly

4 months follow-up result shows that the second generation EXCEL stent rapid and better endothelial, 12 months of follow-up results are expected to achieve perfect endothelial.

CREDIT study is a series clinical trials performed by 40 clinical centers in China.

Aug 8, 2014  the FIM clinical trial 12M OCT and Angio result was first reported on CHC 2014 in Beijing CNCC.

OCT & Angio  results  suggest  a high degree of safety and Efficacy of the second generation EXCEL biodegradable polymer stent.

CREDIT I study indicates the second generation of EXCEL stent system has a good clinical performance.

The second generation EXCEL stent maintains effectiveness, lower Late Lumen Loss (LLL) on the basis of  quickly endothelial change

4M follow-up result shows that the second generation EXCEL stent has rapid and better endothelial, 12M follow-up clinical result demonstrate it achieves perfect endothelialization.